Increased levels of EGFL7 have been linked to increased dissemination of several tumors (Luo et al, 2014; Hansen et al, 2015; Deng et al, 2016) and to a reduced median patient survival time in glioblastoma patients (Huang et al, 2010). Here, EGFL7 is linked to glioblastoma.